MET kinase-IN-2

Modify Date: 2025-08-25 11:25:06

MET kinase-IN-2 structure	Common Name	MET kinase-IN-2
	CAS Number	2101241-90-9	Molecular Weight	562.59
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₃₃H₂₇FN₄O₄	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of MET kinase-IN-2

MET kinase-IN-2 is a potent, selective, orally bioavailable MET kinase inhibitor with an IC50 of 7.4 nM. MET kinase-IN-2 has antitumor activity[1].

Name	MET kinase-IN-2

Description	MET kinase-IN-2 is a potent, selective, orally bioavailable MET kinase inhibitor with an IC50 of 7.4 nM. MET kinase-IN-2 has antitumor activity[1].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Protein Tyrosine Kinase/RTK >> c-Met/HGFR
Target	MET:7.4 nM (IC50)
In Vitro	MET kinase-IN-2 (compound 20j; 72 hours) inhibits U-87 MG, NIH-H460, HT-29, and MKN-45 cell lines with IC50s ranging 2.9 to 4.5 μM[1]. MET kinase-IN-2 inhibits AXL, Flt4, KDR, Mer, TEK, and TYRO3 with IC50s ranging from 16.5 to 198 nM[1].
In Vivo	MET kinase-IN-2 (3-37.5 mg/kg; p.o.; 7 days per week for 3 weeks) exhibits statistically significant tumor growth inhibition in the U-87 MG 24 xeograft model[1]. MET kinase-IN-2 treatment shows that the Cmax, AUC0-∞, T1/2，CL, and F% values are 1.5 µg/mL, 10.7 µg•h/mL, 4.9 hours, 0.5 L/h/kg, and F=32%, respectively[1]. Animal Model: 4-6 weeks old Female nude mice (U-87 MG xenograft model)[1] Dosage: 3, 6, 12.5, 37.5 mg/kg Administration: P.o.; 7 days per week for 3 weeks Result: Induced dose-dependent tumor growth inhibition. Animal Model: Male SD rats[1] Dosage: 5 mg/kg Administration: P.o. (Pharmacokinetic Analysis) Result: Displayed favorable overall PK profiles, with maximal plasma concentration (Cmax=1.5 µg/mL, 5-fold higher to that of IV), plasma exposure (AUC0-∞=10.7 µg•h/mL, 9.7-fold higher to that of IV), half-life (T1/2=4.9 h, 4.9-fold longer to that of IV), total clearance CL (0.5 L/h/kg; 10-fold lower to that of IV), and oral bioavailability (F=32%, 2.7-fold higher to that of IV) after oral dose of 5 mg/kg (10 mg/kg for IV).
References	[1]. Chen T, et al. Discovery of 1,6-naphthyridinone-based MET kinase inhibitor bearing quinoline moiety as promising antitumor drug candidate. Eur J Med Chem. 2020;192:112174.

Molecular Formula	C₃₃H₂₇FN₄O₄
Molecular Weight	562.59

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

Shanghai Nianxing Industrial Co., Ltd
China
Product Name: MET kinase-IN-2
Price: Check
Purity: 98.0%
Delivery: 10 Day
Contact: Yang
Email: sales@echemcloud.com

Get all suppliers and price by the below link:

MET kinase-IN-2 suppliers

MET kinase-IN-2 price